Webinar to Discuss Key Trends Changing the Face of Global Pharma Marketing and Sales

Manhattan ResearchManhattan Research, a global healthcare and pharmaceutical market research company, announces a webinar on April 3, 2009 to review digital marketing trends in emerging markets amidst the need for global best practices. The presentation coincides with the launch of Taking the Pulse® Asia, its latest physician market research and advisory service. The service is part of Manhattan Research's overall insight into global digital trends and focuses on physicians across Japan, China, South Korea, Taiwan, and Australia.

Healthcare and pharmaceutical marketers and other industry stakeholders will use Taking the Pulse® Asia to examine strategic technology, media, channel, and promotional mix trends as well as to benchmark their performance against industry competitors. Subscribers also have access to the Manhattan Research global analyst team for insights on using the market data to shape better-informed marketing and sales strategies. Taking the Pulse® Asia is designed to round out the global digital insights from the European and U.S. physician studies conducted by Manhattan Research, with the goal of giving pharma, biotech, and device clients a comprehensive view of the world physician market.

Taking the Pulse® Asia covers topics such as:

  • Interest in Web 2.0 technologies for health and pharmaceutical information
  • Overall media consumption (traditional vs. new media)
  • Use and impact of sales representatives for clinical and pharmaceutical information
  • Internet access, frequency, types, and activities online
  • Mobile technology adoption, including PDAs/smartphones, MP3/iPods, and SMS messaging
  • Advanced online activities such as online video, blogs, podcasting, and wikis
  • Search engine reliance and frequency
  • Interest in health email newsletters, chat groups, and disease management tools

"Physician technology adoption and integration trends in emerging pharma markets such as China and South Korea are poised to significantly impact the next generation of pharmaceutical marketing," said Meredith Abreu Ressi, Vice President Research at Manhattan Research.

Sign up for Complimentary Webinar – Friday, April 3, 2009

Taking the Pulse® Asia: Physicians and Emerging Information Technologies

Manhattan Research Vice President of Research Meredith Abreu Ressi will host the upcoming webinar, "Taking the Pulse® Asia: Physicians and Emerging Information Technologies" on Friday, April 3, 2009. Ressi will focus on the latest pharma marketing trends from Taking the Pulse® Asia, discuss why these emerging markets are critical to pharma companies, and explain how this knowledge fits into a global marketing strategy.

Key topics include physician adoption and behavior related to the Internet, Web 2.0 technologies, email communication, PDAs/smartphones, search engine reliance, tech-enabled sales reps, and electronic medical records.

Session 1: Friday, April 3, 9:00 AM EST

Session 2: Friday, April 3, 3:00 PM EST

To request an invitation to this exclusive webinar, please visit http://www.manhattanresearch.com/asia or contact Eric Martin at This email address is being protected from spambots. You need JavaScript enabled to view it. or 1-212-367-8886.

For additional Taking the Pulse® Asia product and subscription information, please visit http://www.manhattanresearch.com/products/physician/asia.aspx

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers in the United States, Europe, and Asia. For information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...